EGRX - Eagle Pharmaceuticals, Inc.
| Previous Close | 53.69 |
| Open | 53.68 |
| Bid | 52.68 x 1200 |
| Ask | 63.50 x 800 |
| Day's Range | 52.60 - 53.96 |
| 52 Week Range | 41.51 - 64.94 |
| Volume | 77,054 |
| Avg. Volume | 136,103 |
| Market Cap | 720.609M |
| Beta (5Y Monthly) | 1.10 |
| PE Ratio (TTM) | 29.07 |
| EPS (TTM) | 1.81 |
| Earnings Date | Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 57.00 |
- Simply Wall St.
Eagle Pharmaceuticals (NASDAQ:EGRX) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
- Business Wire
Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY™ (Pemetrexed for Injection)
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its novel product, PEMFEXY™ (pemetrexed for injection), a branded alternative to ALIMTA®.
- Business Wire
Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Disease in Collaboration With University of Pennsylvania
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle") today announced that Eagle and the University of Pennsylvania ("Penn") have agreed on terms of a new exclusive worldwide license agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease, including an agreement to fund additional research and provisions regarding commercialization of products developed under the license.
- Zacks
Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study
Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.
- Business Wire
Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle") today announced that the Company has resubmitted its New Drug Application ("NDA") for RYANODEX® (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke ("EHS"), in addition to body cooling, to the U.S. Food and Drug Administration ("FDA"). Eagle believes that this submission addresses the Complete Response Letter received in July 2017. A Prescription Drug User Fee Act ("PDUFA") date of six months is anticipated for this class of resubmissions.
- Zacks
Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up
Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.
- Simply Wall St.
Is Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) ROE Of 15% Concerning?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- MarketWatch
Tyme stock rises on Eage collaboration for cancer drug
Shares of Tyme Technologies were up 23% in premarket trading on Tuesday after the biotechnology company said it had formed a collaboration with Eagle Pharmaceuticals Inc. to co-promote Tyme's investigational cancer treatment. Eagle's stock gained 3% before the market opened. Per the terms of the agreement, Tyme will receive $20 million upfront and an additional $20 million in milestone payments if certain endpoints are met. If the therapy, oral SM-88, is approved, Eagle is responsible for one-fourth of sales efforts and is expected to receive 15% of net revenue. The treatment has completed mid-stage trials. Tyme's stock has fallen 54% over the last year; Eagle's stock is up 40%. The S&P 500 has gained about 28% over the last 52 weeks.
- Business Wire
Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer
Tyme Technologies, Inc. (Nasdaq: TYME) ("TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), and Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle"), today announced the formation of a U.S. strategic collaboration focused on the co-promotion of TYME’s lead CMBT candidate oral SM-88 in advanced cancers. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells’ protein synthesis, leading to a breakdown of the cancer’s key defenses and cell death. In clinical trials, oral SM-88 has demonstrated complete or partial responses across 15 different cancers, including pancreatic, prostate, sarcoma, breast, lung, and blood cancers with minimal serious grade 3 or higher adverse events.
- Business Wire
Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle") announced today a new research agreement with NorthShore University HealthSystem in Evanston, IL, focused on studying Eagle’s RYANODEX® (dantrolene sodium) for traumatic brain injury (TBI) in animal models.
- Insider Monkey
Eagle Pharmaceuticals Inc (EGRX): Are Hedge Funds Right About This Stock?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- Simply Wall St.
If You Had Bought Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Five Years Ago, You Could Pocket A 336% Gain Today
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) shareholders might be concerned after seeing the share price drop 12% in the...
- Thomson Reuters StreetEvents
Edited Transcript of EGRX earnings conference call or presentation 12-Nov-19 1:30pm GMT
Q3 2019 Eagle Pharmaceuticals Inc Earnings Call
- Zacks
Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -16.13% and -5.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Insider Monkey
Do Hedge Funds Love Eagle Pharmaceuticals Inc (EGRX)?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
- Zacks
Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
